Inhibrx reported a positive Phase II readout for ozekibart in a rare bone cancer with no approved therapies, prompting the company to plan an FDA submission in the second half of 2026. The antibody showed meaningful clinical activity across treated cohorts, supporting regulatory discussions and potential accelerated pathways. The San Diego biotech said efficacy signals were robust enough to justify late‑stage planning and that it will engage regulators on submission design. The program’s rarity and unmet need could favor expedited review options if confirmatory data align. Inhibrx framed the result as a strategic inflection point and signaled business development interest as it prepares to move the program toward registrational endpoints.